Literature DB >> 15668882

Serotype 6B pneumococcal meningitis in an immunocompetent infant immunized with heptavalent pneumococcal conjugated vaccine.

François Angoulvant, Philippe Bidet, Catherine Doit, Guillaume Aubertin, Valérie Soussan, Edouard Bingen, Antoine Bourrillon, Albert Faye.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15668882     DOI: 10.1086/427149

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  4 in total

1.  Report of two cases of aseptic meningitis with persistence of pneumococcal cell wall components in cerebrospinal fluid after Pneumococcal meningitis.

Authors:  François Angoulvant; Julie Lachenaud; Patricia Mariani-Kurkdjian; Guillaume Aubertin; Véronique Houdouin; Mathie Lorrot; Laure de Los Angeles; Edouard Bingen; Antoine Bourrillon; Albert Faye
Journal:  J Clin Microbiol       Date:  2006-09-27       Impact factor: 5.948

2.  Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation.

Authors:  E Bingen; C Levy; E Varon; F de La Rocque; M Boucherat; P d'Athis; Y Aujard; R Cohen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11-30       Impact factor: 3.267

3.  Pediatric osteoarticular infections caused by Streptococcus pneumoniae before and after the introduction of the heptavalent pneumococcal conjugate vaccine.

Authors:  C Lemaître; A Ferroni; C Doit; H Vu-Thien; C Glorion; J Raymond; P Mary; P Wicart; E Bingen; B Ilharreborde; M Lorrot
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-09       Impact factor: 3.267

4.  Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark.

Authors:  Zitta B Harboe; Palle Valentiner-Branth; Helene Ingels; Jeppe N Rasmussen; Peter H S Andersen; Catherine C Bjerre; David Goldblatt; Lindsey Ashton; Mitch Haston; Helle B Konradsen; Lotte Lambertsen
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.